Crown Bioscience Reinforces Global Immuno-Oncology Platform

Crown Bioscience Reinforces Global Immuno-Oncology Platform

Crown Bioscience is strengthening its global immuno-oncology platform at its facilities in Europe, U.S. and Asia to support immuno-oncology client needs with a broad assortment of validated models and services for pharmacodynamics and efficacy studies in animals.

“In response to the growing demand for Immuno-Oncology translational services, CrownBio is now able to offer at its local facilities immunophenotyping analysis, including multi-color flow cytometry, immunohistochemistry and multiplex ELISA on our world-leading collection of Immuno-Oncology models, to rapidly profile and investigate the impact of experimental therapies on both murine and human immune systems,” said Jean Pierre Wery, President of Crown Bioscience, in a press release.

The announcement comes on the heals of the company’s recent launch of the new immuno-oncology model, HuGEMM.

“Up until now, the lack of models available to test the in vivo efficacy of new antibody-based immunotherapies and combination therapies has hindered the research process,” said Wery. “With HuGEMM, there is now a robust model system in place to enable scientists to assess the efficacy of human biologic therapeutics directly without resorting to mouse surrogates.”

Crown Bioscience has a unique collection of certified syngeneic models designed for checkpoint inhibitors besides HuGEMM –  like MiXeno, MuPrime and humanized PDX platforms. All models can be comprehensively profiled using immunophenotyping tools for pharmacodynamic readouts of before-treatment baseline and after-treatment outcomes in order to better understand the effect on the immune system.

“In particular, single cell-based FACS analysis has become a standard and essential tool to investigate the impact of immuno-oncology therapy in both murine and humanized systems in the preclinical setting. Our ability to perform FACS analysis locally as part of our in vivo services offering will undoubtedly represent a key add-on technology for our clients,” added Henry Li, the company’svice president of Translational Oncology. “The ability to gate different sub-populations of T lymphocytes and myeloid compartment provides a rapid way for our clients to understand the impact of both single and combination therapies to significantly extend the reach of potential therapeutic effect across a larger population of patients.”

Leave a Comment

Your email address will not be published. Required fields are marked *